PMID- 21199269
OWN - NLM
STAT- MEDLINE
DCOM- 20110516
LR  - 20181201
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
VI  - 13
IP  - 2
DP  - 2011 Feb
TI  - The effect of pramlintide acetate on glycemic control and weight in patients with 
      type 2 diabetes mellitus and in obese patients without diabetes: a systematic 
      review and meta-analysis.
PG  - 169-80
LID - 10.1111/j.1463-1326.2010.01337.x [doi]
AB  - AIM: the objective of this systematic review and meta-analysis was to assess the 
      effect of pramlintide on glycemic control, weight and incidence of nausea and 
      hypoglycaemia in patients with type 2 diabetes mellitus (T2DM) and in obese 
      patients without diabetes (OBP). METHODS: eight randomized, clinical trials were 
      identified from multiple databases. Qualitative assessments and quantitative 
      analyses were performed. RESULTS: in four T2DM studies (N = 930,duration of 
      studies 16-52 weeks,120-150 mcg/dose BID-TID), all patients received insulin 
      therapy. In four obesity studies (N = 686,duration of studies 6-24 weeks,120-360 
      mcg/dose BID-TID), equivalent volumes of placebo were administered before major 
      meals. Pramlintide significantly reduced haemoglobin A1c (HbA1c) (-0.33% [95% CI 
      -0.51, -0.14], p = 0.004) and weight (-2.57 kg, [95% CI -3.44, -1.70], p < 
      0.00001) versus the control group. More patients in the control group reported 
      hypoglycaemia of any severity versus the pramlintide group (risk ratio 0.84 [95% 
      CI 0.69, 10.3], p = 0.09). In OBP, pramlintide caused a reduction in weight 
      (-2.27 kg [95% CI -2.88, -1.66], p < 0.00001). When event data from both 
      populations were combined, patients randomized to pramlintide were 1.8 times more 
      likely to report nausea of any severity versus control (p = 0.0005). CONCLUSIONS: 
      pramlintide was associated with a small reduction in HbA1c, and a modest 
      reduction in weight in patients with T2DM or OBP. There was increased incidence 
      of nausea but not hypoglycaemia at any time during therapy. Studies about the 
      long-term effect of pramlintide on diabetes- and cardiovascular-related 
      complications and cost-effectiveness analyses are needed.
FAU - Singh-Franco, D
AU  - Singh-Franco D
AD  - College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL 33324, 
      USA. singh@nova.edu
FAU - Perez, A
AU  - Perez A
FAU - Harrington, C
AU  - Harrington C
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Islet Amyloid Polypeptide)
RN  - D3FM8FA78T (pramlintide)
SB  - IM
MH  - Body Weight/*drug effects
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Female
MH  - Humans
MH  - Hypoglycemia/chemically induced/*drug therapy
MH  - Incidence
MH  - Islet Amyloid Polypeptide/*administration & dosage/adverse effects
MH  - Male
MH  - Obesity/complications/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
EDAT- 2011/01/05 06:00
MHDA- 2011/05/17 06:00
CRDT- 2011/01/05 06:00
PHST- 2011/01/05 06:00 [entrez]
PHST- 2011/01/05 06:00 [pubmed]
PHST- 2011/05/17 06:00 [medline]
AID - 10.1111/j.1463-1326.2010.01337.x [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2011 Feb;13(2):169-80. doi: 
      10.1111/j.1463-1326.2010.01337.x.